These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27772772)

  • 21. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG; Vila C
    Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
    Flachenecker P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. THC:CBD spray and MS spasticity symptoms: data from latest studies.
    Rekand T
    Eur Neurol; 2014; 71 Suppl 1():4-9. PubMed ID: 24457846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex
    Carotenuto A; Iodice R; Petracca M; Inglese M; Cerillo I; Cocozza S; Saiote C; Brunetti A; Tedeschi E; Manganelli F; Orefice G
    Acta Neurol Scand; 2017 Apr; 135(4):442-448. PubMed ID: 27500463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Who benefits most from THC:CBD spray? Learning from clinical experience.
    Koehler J
    Eur Neurol; 2014; 71 Suppl 1():10-5. PubMed ID: 24457847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
    Serpell MG; Notcutt W; Collin C
    J Neurol; 2013 Jan; 260(1):285-95. PubMed ID: 22878432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
    Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
    Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.
    Bethoux FA; Farrell R; Checketts D; Sahr N; Berwaerts J; Alexander JK; Skobieranda F
    Mult Scler Relat Disord; 2024 Sep; 89():105740. PubMed ID: 39106541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
    Slof J; Gras A
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):439-41. PubMed ID: 22681512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
    Marková J
    Neurodegener Dis Manag; 2019 Apr; 9(2s):9-13. PubMed ID: 30657024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
    Meuth SG; Vila C; Dechant KL
    Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways.
    Centonze D
    Eur Neurol; 2014; 72 Suppl 1():6-8. PubMed ID: 25278116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J; Feneberg W; Meier M; Pöllmann W
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Moreno Torres I; Sanchez AJ; Garcia-Merino A
    Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
    Di Marzo V; Centonze D
    CNS Neurosci Ther; 2015 Mar; 21(3):215-21. PubMed ID: 25475413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
    Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.